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Abstract
Background: Cerebellar ataxia with sensory ganglionopathy is a rare neurological combination that can occur in
some hereditary ataxias including mitochondrial diseases and in gluten sensitivity. Individually each condition can
be a classic paraneoplastic neurological syndrome. We report a patient with this combination who was diagnosed
with light-chain myeloma ten years after initial presentation.
Case presentation: A 65-year-old Caucasian lady was referred to our Ataxia Clinic because of a 6-year history of
progressive unsteadiness and a 2-year history of slurred speech. Past medical history included arterial hypertension.
The patient was a non-smoker was not consuming alcohol excessively. There was no family history of ataxia.
Neurological examination revealed prominent gaze-evoked nystagmus, heel to shin ataxia, gait ataxia, reduced
reflexes and loss of vibration sensation in the legs.
Cerebellar ataxia was confirmed using magnetic resonance spectroscopy of the cerebellum and sensory
ganglionopathy using neurophysiological assessments including blink reflex study. A muscle biopsy that was
arranged to explore the possibility of mitochondrial disease revealed amyloidosis. Urinalysis confirmed the presence
of light chains. A bone marrow biopsy confirmed the diagnosis of light chain multiple myeloma.
Conclusions: Whilst it could be argued that this could simply be a coincidence, the rarity of these conditions and
the absence of an alternative aetiology for the neurological dysfunction argue in favour of a paraneoplastic
phenomenon.
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Background
Ataxia is a term used to describe poor control of
movement, which manifests with unsteadiness and poor
co-ordination. Ataxia can be mainly classified into cere-
bellar and sensory.
Cerebellar ataxia, resulting from a dysfunction of the
cerebellum, can be inherited (e.g. Friedreich’s ataxia and
spinocerenellar ataxias, known as SCAs) or acquired
(such as immune mediated and paraneoplastic) [1].
Sensory ataxia results from a loss of proprioception
and is usually caused by dysfunction within the sensory
pathways, both peripheral and central. Sensory ataxia
can therefore be seen in neuropathies that involve sen-
sory fibers in isolation or in combination with motor
fiber involvement. Sensory ataxia is more prominent in
pure sensory neuropathies also called sensory neurono-
pathies [2]. Causes for sensory neuropathies or neurono-
pathies can be immune mediated [3] e.g. gluten
sensitivity [4] Sjogren’s syndrome and paraneoplastic [5].
Cerebellar ataxia combined with sensory neuronopathy
is a relatively rare neurological picture, which can be
seen in some hereditary ataxias [2] (e.g. Friedreich’s
ataxia and SCA18, mitochondrial disease) or as a result
of exposure to toxins (e.g. amiodarone [6]).
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We present a case with this combination with a rather
unusual aetiology.
Case presentation
A 65-year-old Caucasian lady was referred to our Ataxia
Clinic because of a 6-year history of progressive un-
steadiness and a 2-year history of slurred speech. Past
medical history included arterial hypertension. The pa-
tient was a non-smoker was not consuming alcohol ex-
cessively. There was no family history of ataxia.
Neurological examination revealed prominent gaze-
evoked nystagmus, heel to shin ataxia, gait ataxia, reduced
reflexes and loss of vibration sensation in the legs.
Routine blood tests included full blood count, erythro-
cyte sedimentation rate, urea, creatinine, electrolytes,
liver function tests, thyroid function tests, random glu-
cose, Vitamin B12, folate, Vitamin E and folate, were all
normal.
Extensive immunology screening included immuno-
globulins and serum electrophoresis, antinuclear anti-
bodies (ANA), anti-double stranded DNA (anti-dsDNA)
antibodies, GAD antibodies, anti-neutrophil cytoplasmic
antibodies (ANCA), thyroid peroxidase (TPO) anti-
bodies, endomysium antibodies, transglutaminase anti-
bodies and gliadin antibodies. From those, the IgA and
IgM titer were low (IgA 0.63 g/L, normal values 0.8–4.0
and IgM 0.22 g/L, normal values 0.5–2.0), with no elec-
trophoretic abnormality noted. C-ANCA antibodies
were positive but PR3 antibodies were negative. Interest-
ingly, the patient had the DQ8 human leukocyte antigen
(HLA) serotype, which is commonly linked to auto-
immune diseases, including coeliac disease [7].
The MRI of the brain was unremarkable for the pa-
tient’s age, with no evidence of cerebellar atrophy in par-
ticular. However, the magnetic resonance spectroscopy
(MRS) of the cerebellar vermis revealed a low N-acetyl
aspartate (NAA) to Creatine (Cr) area ratio (NAA/Cr
0.95, normal values [8] > 1.0) (Fig. 1A). Low NAA/Cr ra-
tio implies abnormal metabolic activity within the area
of interest (voxel). It can be used as an indicator to cere-
bellar dysfunction [9].
Sensory conduction studies of the right median, right
ulnar, right radial and both sural nerves showed attenu-
ated amplitudes, when the motor conduction studies of
the right median, right ulnar and right peroneal nerves
were within normal limits. The electrically elicited blink
reflex was tested bilaterally and revealed an asymmetric
involvement of the trigeminal/facial nerve pathways,
suggesting a diagnosis of sensory ganglionopathy [10].
As the combination of cerebellar ataxia with sensory
ganglionopathy can be seen as part of hereditary ataxias,
including mitochondrial diseases, the patient was ini-
tially tested and was negative for the common genetic
ataxias (Fridriech’s ataxia, SCA1, SCA2, SCA3, SCA6
and SCA7). Subsequent further genetic testing using
new generation sequencing was also negative and
included the following genes; ABCB7, AFG3L2, APTX,
ATM, ATP1A2, ATP1A3, ATP7B, C10orf2, CACNA1A,
CACNB4, CYP2U1, CYP27A1, DDHD2, EEF2, FGF14,
FTL, FXN, GBA, GBA2, IFRD1, ITPR1, KCNA1,
KCNC3, KCND3, MTPAP, PDYN, PRKCG, PRRT2,
SACS, SCN1A, SETX, SIL1, SLC16A2, SLC1A3,
SLC2A1, SPG7, SPTBN2, TGM6, TTBK2, TTPA,
VAMP1, ZFYVE26 (Additional file 1).
Clinical course
The patient has been followed-up on a 6 monthly basis
and remained relatively stable. Thirty months after the
initial presentation to our clinic repeat nerve conduction
studies and repeat MRI and MRS were arranged. The
nerve conduction studies showed further deterioration
of the sensory ganglionopathy. The MRI of the brain
showed is mild to moderate atrophy of the vermis [11]
(grade 2) and mild atrophy [11] (grade 1) of the hemi-
spheres (Fig. 2), when the MRS showed further deterior-
ation of the NAA/Cr ratios of the cerebellum (Fig. 1B).
In order to rule out mitochondrial disease the com-
mon mitochondrial mutations (MELAS, MERRF, NARP,
POLG1) were tested and were negative and a muscle bi-
opsy was arranged. Transmission electron microscopy of
glutaraldehyde fixed muscle revealed the presence of
endomysial amyloid. Histologically, no inflammation, ne-
crosis, or inclusions were seen (Fig. 3). Urinalysis con-
firmed the presence of light chains. A bone marrow
biopsy was performed confirming the diagnosis of light
chain multiple myeloma. Scintigraphy showed predom-
inantly cardiac involvement and the patient was referred
for further treatment.
Table 1 summarizes the nerve conduction tests and
the MRS findings across the clinical course of the
patient.
Discussion
Despite the extensive diagnostic work up for cerebellar
ataxia combined with sensory ganglionopathy our pa-
tient was only diagnosed with light-chain multiple mye-
loma 10 years after the onset of the neurological
symptoms. Until then, our working diagnosis based on
extensive investigations was idiopathic sporadic cerebel-
lar ataxia with sensory ganglionopathy, possibly auto-
immune mediated.
Light-chain myeloma accounts for about 20% of
multiple myeloma cases [12]. Three quarters of the
light-chain myelomas are of kappa light chain and in
only 25% the histological finding is the deposition of
lambda light chain [12]. Therefore, the lambda light
chain myeloma accounts for only the 5% of all mul-
tiple myeloma cases.
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Neurological manifestations of light chain myeloma
can be central or peripheral. Central manifestations most
commonly result from cerebral or cerebellar plasmacyto-
mas [13]. Occasionally patients may present with myel-
opathy secondary to paraspinal plasmacytomas [14].
Peripheral manifestations include radiculopathy second-
ary to fractures of the vertebrae, amyloid neuropathy
and peripheral neuropathies related to a remote effect of
the monoclonal gammopathy or to amyloidosis, in
addition to the neurotoxicity of treatments, such as thal-
idomide and bortezomib [15].
Amyloid neuropathy occurs secondary to deposition of
amyloid in the peripheral nerves. It usually leads to a
symmetrical sensorimotor axonal neuropathy almost
always with autonomic involvement. In our case, as im-
plied by the nerve conduction studies, the pathology had
to be confined to the dorsal root ganglia. In addition the
patient had no autonomic dysfunction. It is therefore
highly unlikely that the sensory ganglionopathy, that the
patient had, was related to the amyloidosis.
Sub-acute sensory ganglionopathy as a paraneoplastic
phenomenon is commonly associated with small cell
lung cancer [16]. Other tumors associated with parano-
plastic sensory neuronopathy include breast cancer,
prostate cancer, ovarian cancer, bladder cancer, Hodgkin
Lymphoma and sarcoma [17]. Cerebellar degeneration
as a paraneoplastic phenomenon is associated with a
broad spectrum of tumors including ovarian cancer,
Fig. 1 Spectral data obtained at intermediate echo-time by single-voxel 1H magnetic resonance spectroscopy of the cerebellar vermis. The
amplitude of the resonances is measured on the Y-axis using an arbitrary scale. A low N-acetyl aspartate (NAA) to creatine (Cr) area ratio was
found at first assessment with NAA/Cr 0.95, normal values >1.08 (A). MRS findings at 30 months show deterioration of NAA/Cr with a drop from
0.95 to 0.83 (B)
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breast cancer, lung cancer and Hodgkin’s lymphoma
[18]. To our knowledge, multiple myeloma has not been
linked to any paraneoplastic neurological syndrome.
The recommended diagnostic criteria for paraneoplas-
tic neurological syndromes [19] suggest that the cancer
has to develop within five years of the diagnosis of
neurological disorder. This time period has been based
on reports showing that in the majority of cases the
interval between the paraneoplastic neurological syn-
drome and the diagnosis of cancer is less than 5 years.
In our case, the interval between the onset of the neuro-
logical symptoms and the diagnosis of the malignancy
was ten years.
Conclusions
To our knowledge this is the first case of cerebellar
ataxia with sensory ganglionopathy associated with light
chain myeloma. Whilst it could be argued that this could
simply be a coincidence, the rarity of these conditions
and the absence of an alternative aetiology for the
neurological dysfunction argues in favour of a paraneo-
plastic phenomenon. As the myeloma in this case is not
curable the chances of recovery with chemotherapy are
remote. Indeed on the latest MR imaging there is signifi-
cant progression of the spectroscopic abnormalities as
well as the development of cerebellar atrophy.
Fig. 3 a Electron micrograph (original magnification × 2,600) of a
mass of randomly arranged straight amyloid fibrils around a capillary
(at the top of the image), and a skeletal muscle myocyte (at the
bottom). b Electron micrograph (original magnification × 20,000)
showing randomly arranged straight amyloid fibrils
Fig. 2 a Axial MRI T2 image showing atrophy of the cerebellar
hemispheres (grade 1). b Sagittal MRI image, showing vermian
grade 2 atrophy
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